| Catalog Number | Product | Size | Price | |
|---|---|---|---|---|
| A1038-100 | Anti-human RNF43 mIgG2b | 100µg | $185 | Order |
| A1038-200 | Anti-human RNF43 mIgG2b | 200µg | $325 | Order |
| Catalog Number | A1038 |
|---|---|
| Product Name | Anti-human RNF43 |
| Source | Purified mouse antibody from hybridoma |
| Clone | R45S2 |
| Species Reactivity | Human |
| Isotype | Mouse IgG2b |
| Purity | >95% |
| Formulation | 1xPBS, pH7.0. Sterile |
| Stability & Storage | 1 month at 4oC; 12 months at <-20oC; Avoid repeated freeze-thaw |
| Protein Aggregation | Not obvious on SDS-PAGE |
| Application | Flow cytometry, ELISA, cell-based assay |
| Product Datasheet: | Download PDF |
Detection of human RNF43 expression on human RNF43-CHO-K1 stable cell line (Cat. #C3072) using the anti-human RNF43 mIgG2b antibody (Cat. #A1038).
Detection of human RNF43 expression on human adenocarcinoma cell line HCT-15 using the anti-human RNF43 mIgG1 antibody (Cat. #A1038).
RNF43, short for Ring Finger Protein 43, is a significant component in cellular signaling pathways, particularly the Wnt signaling pathway. Recognized as an E3 ubiquitin ligase, RNF43 aids in tagging proteins for degradation. RNF43's primary function lies in regulating cell surface receptors, specifically by targeting Frizzled receptors, which are integral to Wnt signaling, for ubiquitination and subsequent degradation. This activity modulates the Wnt pathway, a critical regulator of cell proliferation, differentiation, and embryonic development. Tissue expression is found throughout the body but particularly in high amounts in the gastrointestinal tract and colon. RNF43 mutations or alterations have been identified in certain cancers, notably in colorectal cancer and some types of gastric cancer. These alterations often result in increased Wnt signaling due to the absence of proper regulation by RNF43, contributing to uncontrolled cell growth and tumorigenesis. Consequently, this has piqued significant interest in RNF43 as a potential therapeutic target for cancer treatment.
de Lau W, Peng WC, Gros P, Clevers H. The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength. Genes Dev. 28(4):305-16. 2014.
Giannakis M, Hodis E, Jasmine Mu X, et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet. 46(12):1264-1266. 2014.
Zebisch M, Xu Y, Krastev C, et al. Structural and molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by the Wnt agonist R-spondin. Nat Commun. 4:2787. 2013.